JOHNSON & JOHNSON - 09 Apr 2024 Form 3 Insider Report for Contineum Therapeutics, Inc. (CTNM)

Reporting relationship: 10%+ Owner
Issuer ticker: CTNM
Reported as of: 09 Apr 2024
Net transaction value: $0
SEC form: 3
Accepted by SEC: 10 Apr 2024, 17:05:42 UTC
Prior SEC filing: 06 Mar 2024
Next SEC filing: 10 Nov 2025
Source filing: View source filing
Reporting owner signature: Johnson & Johnson By: /s/ Marc Larkins, Secretary

Key filing fact

JOHNSON & JOHNSON filed Form 3 for Contineum Therapeutics, Inc. (CTNM) on 10 Apr 2024.

Key facts

This page summarizes JOHNSON & JOHNSON's Form 3 filing for Contineum Therapeutics, Inc. (CTNM).
0 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 10 Apr 2024, 17:05.

Change

Previous filing in this sequence was filed on 06 Mar 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CTNM holding

Class A Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,979,173
Date: 09 Apr 2024
Ownership: See footnote
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The securities reported as indirectly beneficially owned by Johnson & Johnson are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of Johnson & Johnson.